Table 5.

Tyrosine kinase inhibitors targeting the angiogenic pathway currently in clinical development in breast cancer

Drug	Target
Sunitinib	VEGFR2, PDGFR-β, FLT3, c-Kit
Sorafenib	VEGFR1, 2 and 3, PDGFR-β, FLT3, c-Kit, Raf
Pazopanib	VEGFR1, 2 and 3, PDGFR-α/β, c-Kit
Vatalanib	VEGF1, 2 and 3, PDGFR, c-Kit, c-Fos
Cediranib	VEFGR1, 2 and 3, PDGFR, c-Kit
Vandetanib	VEGFR2, EGFR, RETS
AMG 706	VEGFR1, 2 and 3, PDGFR-β, c-kit
Axitinib	VEGFR1, 2 and 3, PDGFR, c-Kit

EGFR, epidermal growth factor receptor; PDGFR, platelet-derived growth factor receptor; VEGFR, vascular endothelial growth factor receptor.